









Markets
/
Stocks
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

328.240USD

+20.190+6.55%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

17.03BMarket Cap

137.06P/E TTM



Alnylam Pharmaceuticals Inc

328.240

+20.190+6.55%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alnylam Pharmaceuticals Inc

Currency: USD Updated: 2026-03-25

Key Insights

Alnylam Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 9 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 445.97.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alnylam Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

9 / 157

Overall Ranking

44 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Alnylam Pharmaceuticals Inc Highlights

StrengthsRisks

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 103.14% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 137.25, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 132.38M shares, decreasing 0.01% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 2.06K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

445.971

Target Price

+45.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Alnylam Pharmaceuticals Inc is 8.71, ranking 29 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.10B, representing a year-over-year increase of 84.95%, while its net profit experienced a year-over-year increase of 322.56%.

Score

Industry at a Glance

Previous score

8.71

Change



Financials

7.81

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.13

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.61

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Alnylam Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Alnylam Pharmaceuticals Inc is 7.42, ranking 69 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 137.25, which is 961.94% below the recent high of 1457.49 and 472.82% above the recent low of -511.69.

Score

Industry at a Glance

Previous score

7.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 9/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Alnylam Pharmaceuticals Inc is 7.80, ranking 94 out of 157 in the Pharmaceuticals industry. The average price target is 500.00, with a high of 580.00 and a low of 236.00.

Score

Industry at a Glance

Previous score

7.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

445.971

Target Price

+44.77%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Alnylam Pharmaceuticals Inc

ALNY

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Alnylam Pharmaceuticals Inc is 8.96, ranking 12 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 342.46 and the support level at 307.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.87

Change

2.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

2.571

Neutral

RSI(14)

53.608

Neutral

STOCH(KDJ)(9,3,3)

60.081

Buy

ATR(14)

10.725

High Vlolatility

CCI(14)

120.835

Buy

Williams %R

2.612

Overbought

TRIX(12,20)

-0.269

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

313.336

Buy

MA10

315.145

Buy

MA20

319.710

Buy

MA50

333.397

Sell

MA100

379.705

Sell

MA200

392.673

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Alnylam Pharmaceuticals Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 102.07%, representing a quarter-over-quarter decrease of 0.31%. The largest institutional shareholder is The Vanguard, holding a total of 13.49M shares, representing 10.17% of shares outstanding, with 2.04% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

16.43M

-2.21%

Fidelity Management & Research Company LLC

15.91M

+5.68%

The Vanguard Group, Inc.

Star Investors

13.51M

+2.02%

BlackRock Institutional Trust Company, N.A.

6.59M

+0.81%

Capital Research Global Investors

7.22M

+0.43%

JP Morgan Asset Management

3.87M

+115.83%

State Street Investment Management (US)

3.08M

-2.89%

Geode Capital Management, L.L.C.

2.50M

+4.19%

Baillie Gifford & Co.

Star Investors

2.79M

-8.00%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Alnylam Pharmaceuticals Inc is 6.33, ranking 56 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Alnylam Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.